New drug could reverse treatment resistance in advanced multiple myeloma

March 27, 2020

Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease - a point when many patients currently run out of options. These promising results could pave the way for the new drug to be tested in patients.

Multiple myeloma is a cancer that affects cells in the bone marrow that produce antibodies - small molecules that fight infections in the body. Multiple myeloma is not considered to be a curable cancer and almost all patients eventually relapse. In the UK, almost 6,000 people are diagnosed with multiple myeloma every year - that's 16 people per day.

The new drug, called FL118, has previously shown promise when tested on colon and head and neck cancer cells in the lab. This new study, led by Dr Tuna Mutis and funded by Worldwide Cancer Research and the Dutch Cancer Society, was recently published in the journal Haematologica.

Cancer cells can become resistant to treatment by recruiting surrounding healthy cells to support them. The researchers found that not only is FL118 effective at killing multiple myeloma cells when they are surrounded by these support cells, but it was also able to reverse treatment resistance. This suggests the drug could have potential to treat patients that are no longer responding to standard therapies.

Using patient samples of newly diagnosed and relapsed or treatment resistant patients, FL118 was found to be more effective against cancer cells from advanced disease patients, than the newly diagnosed cases. The researchers also found that FL118 enhanced the effect of melphalan and bortezomib - two drugs commonly used in the treatment of multiple myeloma. When tested in a mouse model of multiple myeloma, FL118 was able to reduce tumour volume to almost one sixth of its original size and delayed tumour growth for up to 5 weeks.

According to the researchers, FL118 could be used in combination with currently used drugs to overcome treatment resistance. They suggest that FL118 has the potential to be highly efficient in relapsed or treatment resistant patients - a group that urgently needs new therapeutic options.

Dr Tuna Mutis explained the next steps: "The first step towards using this compound in the clinic is to do a phase one trial, which judges the safety of the drug. Our collaborators, who also provided this compound, are now planning this trial. In addition to this, we are also testing whether this new drug could improve immune therapy. This would be another important effect, which could demonstrate its usefulness in a wide variety of cancers - not just multiple myeloma."

Dr Helen Rippon, Chief Executive of Worldwide Cancer Research, said: "This study is close to our heart as Worldwide Cancer Research's founder, Dr Colin Thomson, sadly passed away from multiple myeloma. The new findings take the first step towards a new drug that could one day be used to treat people with advanced multiple myeloma. As with any new treatment, there is a long journey ahead, but research such as this lays the groundwork for clinical trials in the future. Multiple myeloma is an incurable cancer that almost always comes back - even after seemingly successful treatment. Treatment resistance is a huge problem in cancer patients and exciting discovery research like this tackles this issue head on. We need to make sure that more bold new ideas like this are funded if we want to keep one step ahead of cancer."
Issued by Worldwide Cancer Research. For all enquiries, please contact:

Charlott Repschläger
Science Communications Officer
Direct dial: +44 (0) 131 370 0345


Worldwide Cancer Research is Scotland's only cancer research charity, funding discovery research into any type of cancer - because the first step is the most important. We back the brightest minds in cancer research all around the world in their quests to find new ways to prevent, diagnose and treat cancer. The charity receives no government funding and we rely solely on the funds of our supporters to start new cancer cures across the world so that one day, we can stop the suffering caused by cancer.

Since Worldwide Cancer Research was founded in 1979, cancer survival rates have doubled, but cancer remains the world's second biggest killer. In the last 40 years we have:But 1 in 2 people are still diagnosed with some form of cancer during their lifetime. For us, that's 1 in 2 too many. Bold research will cure cancer - but we can't do it alone.

Visit to find out how you can help us search the world for the cures to cancer.

Worldwide Cancer Research

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to